Ruxolitinib Gel(Hangzhou Zhongmei Huadong)

芦可替尼凝胶（杭州中美华东）

Report date: 2025/10/24 14:47:26

Base Information

Drug NameRuxolitinib Gel(Hangzhou Zhongmei Huadong)
Drug Alias NameHDM3010（化药2.1类）HDM3010HDM-3010
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsPrurigo NodularisVitiligo
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuadong Medicine (Xi'An) Bodyguard Pharmaceutical Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisVitiligo
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A